Polyisoprenylated cysteinyl amide inhibitors: a novel approach to controlling cancers with...

CH Li, MH Chan, SM Liang, YC Chang, M Hsiao - BBA advances, 2022 - Elsevier

Filopodia are cellular protrusions that respond to a variety of stimuli. Filopodia are formed
when actin is bound to the protein Fascin, which may play a crucial role in cellular …

被引用次数：5 相关文章所有 9 个版本

[PDF] plos.org

Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces …

MD Gregory, K Ofosu-Asante, JMS Lazarte, PE Puente… - PloS one, 2024 - journals.plos.org

KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …

Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors

N Tawfeeq, Y Jin, NS Lamango - Cancers, 2021 - mdpi.com

Simple Summary RAS G-protein genes are frequently mutated and drive the progression of
about 30% of human cancers. Polyisoprenylated cysteinyl amide inhibitors (PCAIs) offer a …

被引用次数：4 相关文章所有 6 个版本

[PDF] semanticscholar.org

[PDF][PDF] Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors. Cancers (Basel). 2021; 13: 5757

N Tawfeeq, Y Jin, NS Lamango - 2021 - pdfs.semanticscholar.org

Abnormalities of the MAPK pathway play vital roles in cancer initiation and progression. RAS
GTPases that are key upstream mediators of the pathway are mutated in 30% of human …

被引用次数：3 相关文章

Targeting KRAS Mutant Cancers with Polyisoprenylated Cysteinyl Amide Inhibitors

N Tawfeeq - 2021 - search.proquest.com

Abnormalities of the MAPK pathway play vital roles in cancer initiation and progression. RAS
GTPases that are key upstream mediators of the pathway are mutated in 20%–30% of …